CD8‐positive peripheral T cell lymphoma in a patient following long‐term nivolumab for advanced lung adenocarcinoma: A case report
Abstract A 54‐year‐old male smoker presented with hemoptysis. Advanced lung adenocarcinoma, cT1cN3M1b, stage IVB, was diagnosed. Enlargement of multiple intraperitoneal and inguinal lymph nodes and peripheral atypical lymphocytosis appeared after 33 cycles of second‐line treatment with nivolumab, an...
Main Authors: | Keigo Koda, Mikio Toyoshima, Shusuke Yazawa, Atsuki Fukada, Haruhiko Sugimura, Takafumi Suda |
---|---|
Format: | Article |
Language: | English |
Published: |
Wiley
2021-06-01
|
Series: | Thoracic Cancer |
Subjects: | |
Online Access: | https://doi.org/10.1111/1759-7714.13966 |
Similar Items
-
Emerging treatment options for the management of Hodgkin's lymphoma: clinical utility of Nivolumab
by: Bond DA, et al.
Published: (2017-05-01) -
Nivolumab in relapsed/refractory Hodgkin Lymphoma patients, single center experiences
by: Ramazan Acar, et al.
Published: (2020-12-01) -
PD-1 Blockade with Nivolumab as a New Immunotherapy for Classical Hodgkin’s Lymphoma
by: EA Demina
Published: (2018-07-01) -
Efficacy and safety of nivolumab in the treatment of relapsed/refractory classical Hodgkin’s lymphoma: Pavlov First Saint Petersburg State Medical University experience
by: K. V. Lepik, et al.
Published: (2019-01-01) -
Nivolumab-associated cutaneous T-cell lymphoma
by: Jennifer A. Marks, MD, et al.
Published: (2021-03-01)